Business

Bayer Finalizes Multi-Billion Dollar Settlement in Roundup Cancer Litigation

A Missouri judge has granted final approval to a settlement involving Bayer that could cost up to $7.25 billion for individuals claiming the weed killer Roundup caused their cancer.

Bayer has secured final approval for a massive settlement that could cost the agrochemical and biotech company up to $7.25 billion, bringing resolution to thousands of lawsuits alleging that the weed killer Roundup causes cancer. On Friday, a judge in Missouri gave the final approval for the nationwide class action, which is intended to provide compensation to people who have been or will be diagnosed with non-Hodgkin lymphoma.

The settlement structure allows affected individuals to receive payments ranging from $10,000 to $165,000. Compensation amounts are determined by several factors, including the age at which a patient was diagnosed, as well as the level of their exposure to glyphosate—the primary ingredient in Roundup—during work in agriculture or other relevant occupations.

In a statement following the ruling, Bayer CEO Bill Anderson described the settlement as a “decisive milestone” that will “mitigate the risks” associated with both pending and future litigation. Timothy Boyer, the presiding judge for the circuit court, noted that the settlement is “among the largest in the history of mass tort personal-injury class action settlements.”

Christopher Seeger, the attorney representing the plaintiffs, stated that “Today’s final approval order delivers guaranteed compensation to Roundup cancer victims who have waited more than a decade for justice.”

This agreement marks a significant additional expenditure for Bayer, which previously agreed to pay between $10 billion and $11 billion to resolve more than 100,000 other Roundup-related claims. Despite these settlements, the company maintains its stance that Roundup is safe and has steadfastly denied that the product causes cancer.

The safety of glyphosate remains a subject of debate. Over a decade ago, the World Health Organization’s cancer agency classified the chemical as probably carcinogenic to humans, a conclusion supported by various environmental health scientists as recently as this year. Conversely, the U.S. Environmental Protection Agency (EPA) has stated it “did not identify risks of concern from glyphosate uses, including for cancer,” although the agency is currently reviewing evidence related to human health after facing pressure from advocates and scientists.

Political tensions surrounding the herbicide persist. While supporters of Health Secretary Robert F. Kennedy Jr. have identified glyphosate safety as a central issue for the “Make America Healthy Again” agenda, the current administration has taken steps to support the herbicide manufacturer. This includes siding with Bayer in a recent U.S. Supreme Court case regarding the failure to warn consumers about potential risks and issuing an executive order aimed at promoting the domestic production of glyphosate. Several years ago, Bayer removed glyphosate from its residential products, though it continues to be utilized in the agricultural industry.

Mia Reynolds

Mia Reynolds covers companies, entrepreneurship, leadership, and changing industries. She turns complex business developments into accessible stories, helping readers follow corporate decisions, market shifts, and trends influencing the global business landscape.
Back to top button